Intra-Cellular Therapies Toekomstige groei
Future criteriumcontroles 6/6
Intra-Cellular Therapies zal naar verwachting groeien in winst en omzet met respectievelijk 68.5% en 33.5% per jaar. De winst per aandeel zal naar verwachting groeien met 68.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 37.2% zijn.
Belangrijke informatie
68.5%
Groei van de winst
68.4%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.6% |
| Inkomstengroei | 33.5% |
| Toekomstig rendement op eigen vermogen | 37.2% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 04 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,404 | 395 | 424 | 492 | 13 |
| 12/31/2025 | 938 | 51 | 78 | 65 | 15 |
| 12/31/2024 | 676 | -69 | -54 | 2 | 13 |
| 9/30/2024 | 614 | -86 | -63 | -62 | N/A |
| 6/30/2024 | 565 | -84 | -61 | -61 | N/A |
| 3/31/2024 | 514 | -111 | -99 | -98 | N/A |
| 12/31/2023 | 464 | -140 | -124 | -124 | N/A |
| 9/30/2023 | 420 | -155 | -162 | -161 | N/A |
| 6/30/2023 | 366 | -184 | -190 | -189 | N/A |
| 3/31/2023 | 311 | -228 | -248 | -247 | N/A |
| 12/31/2022 | 250 | -256 | -271 | -270 | N/A |
| 9/30/2022 | 188 | -298 | -305 | -304 | N/A |
| 6/30/2022 | 138 | -321 | -331 | -330 | N/A |
| 3/31/2022 | 103 | -304 | -296 | -295 | N/A |
| 12/31/2021 | 84 | -284 | -260 | -260 | N/A |
| 9/30/2021 | 71 | -259 | -255 | -255 | N/A |
| 6/30/2021 | 56 | -237 | -239 | -239 | N/A |
| 3/31/2021 | 38 | -232 | -227 | -227 | N/A |
| 12/31/2020 | 23 | -227 | -230 | -230 | N/A |
| 9/30/2020 | 10 | -207 | -196 | -197 | N/A |
| 6/30/2020 | 3 | -187 | -163 | -163 | N/A |
| 3/31/2020 | 1 | -160 | -144 | -144 | N/A |
| 12/31/2019 | 0 | -148 | -129 | -128 | N/A |
| 9/30/2019 | N/A | -148 | -123 | -122 | N/A |
| 6/30/2019 | N/A | -155 | -122 | -121 | N/A |
| 3/31/2019 | N/A | -154 | -127 | -127 | N/A |
| 12/31/2018 | N/A | -155 | -119 | -118 | N/A |
| 9/30/2018 | 0 | -145 | -115 | -114 | N/A |
| 6/30/2018 | 0 | -126 | N/A | -100 | N/A |
| 3/31/2018 | 0 | -106 | N/A | -91 | N/A |
| 12/31/2017 | 0 | -98 | N/A | -80 | N/A |
| 9/30/2017 | 0 | -95 | N/A | -84 | N/A |
| 6/30/2017 | 0 | -102 | N/A | -99 | N/A |
| 3/31/2017 | 0 | -116 | N/A | -88 | N/A |
| 12/31/2016 | 0 | -116 | N/A | -91 | N/A |
| 9/30/2016 | 0 | -118 | N/A | -98 | N/A |
| 6/30/2016 | 0 | -120 | N/A | -89 | N/A |
| 3/31/2016 | 0 | -110 | N/A | -106 | N/A |
| 12/31/2015 | 0 | -105 | N/A | -102 | N/A |
| 9/30/2015 | 0 | -91 | N/A | -73 | N/A |
| 6/30/2015 | 0 | -65 | N/A | -57 | N/A |
| 3/31/2015 | 0 | -48 | N/A | -32 | N/A |
| 12/31/2014 | 1 | -31 | N/A | -23 | N/A |
| 9/30/2014 | 1 | -24 | N/A | -25 | N/A |
| 6/30/2014 | 2 | -22 | N/A | -26 | N/A |
| 3/31/2014 | 2 | -26 | N/A | -27 | N/A |
| 12/31/2013 | 3 | -27 | N/A | -23 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat ITCI de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).
Winst versus markt: Er wordt verwacht dat ITCI de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat ITCI binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van ITCI ( 33.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van ITCI ( 33.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ITCI zal naar verwachting over 3 jaar hoog zijn ( 37.2 %)